rs186924074
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 1P and 1B. PP3BS2_Supporting
The NM_000053.4(ATP7B):āc.1922T>Cā(p.Leu641Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000828 in 1,614,082 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000053.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATP7B | NM_000053.4 | c.1922T>C | p.Leu641Ser | missense_variant | 6/21 | ENST00000242839.10 | NP_000044.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000585 AC: 89AN: 152198Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000489 AC: 122AN: 249584Hom.: 0 AF XY: 0.000473 AC XY: 64AN XY: 135410
GnomAD4 exome AF: 0.000854 AC: 1248AN: 1461766Hom.: 2 Cov.: 31 AF XY: 0.000802 AC XY: 583AN XY: 727198
GnomAD4 genome AF: 0.000584 AC: 89AN: 152316Hom.: 0 Cov.: 32 AF XY: 0.000604 AC XY: 45AN XY: 74492
ClinVar
Submissions by phenotype
Wilson disease Uncertain:7Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 01, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 20, 2022 | The ATP7B c.1922T>C; p.Leu641Ser variant (rs186924074) is reported in the literature in individuals affected with Wilson disease (Bost 2012, Coffey 2013, Cox 2005, Vrabelova 2005). This variant is reported in ClinVar (Variation ID: 420002), and is found in the general population with an overall allele frequency of 0.046% (130/280986 alleles) in the Genome Aggregation Database. The leucine at codon 641 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.93). However, functional analyses of the variant protein show similar copper trafficking compared to wild type (Braiterman 2014, de Bie 2007). Due to conflicting information, the clinical significance of the p.Leu641Ser variant is uncertain at this time. References: Bost M et al. Molecular analysis of Wilson patients: direct sequencing and MLPA analysis in the ATP7B gene and Atox1 and COMMD1 gene analysis. J Trace Elem Med Biol. 2012;26(2-3):97-101. PMID: 22677543. Braiterman LT et al. Distinct phenotype of a Wilson disease mutation reveals a novel trafficking determinant in the copper transporter ATP7B. Proc Natl Acad Sci U S A. 2014;111(14):E1364-E1373. PMID: 24706876. Coffey AJ et al. A genetic study of Wilson's disease in the United Kingdom. Brain. 2013;136(Pt 5):1476-1487. PMID: 23518715. Cox DW et al. Twenty-four novel mutations in Wilson disease patients of predominantly European ancestry. Hum Mutat. 2005;26(3):280. PMID: 16088907. de Bie P et al. Distinct Wilson's disease mutations in ATP7B are associated with enhanced binding to COMMD1 and reduced stability of ATP7B. Gastroenterology. 2007;133(4):1316-1326. PMID: 17919502. Vrabelova S et al. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol Genet Metab. 2005;86(1-2):277-285. PMID: 15967699. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 08, 2021 | NM_000053.3(ATP7B):c.1922T>C(L641S) is a missense variant classified as a variant of uncertain significance in the context of Wilson disease. L641S has been observed in cases with relevant disease (PMID: 30232804, 15967699, 16088907, 22677543). Functional assessments of this variant are available in the literature (PMID: 24706876, 17919502). L641S has been observed in population frequency databases (gnomAD: NFE 0.08%). In summary, there is insufficient evidence to classify NM_000053.3(ATP7B):c.1922T>C(L641S) as pathogenic or benign. Please note: this variant was assessed in the context of healthy population screening. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change replaces leucine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 641 of the ATP7B protein (p.Leu641Ser). This variant is present in population databases (rs186924074, gnomAD 0.08%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with Wilson disease (PMID: 15967699, 16088907, 22677543, 23518715, 34400371). ClinVar contains an entry for this variant (Variation ID: 420002). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on ATP7B protein function. Experimental studies have shown that this missense change does not substantially affect ATP7B function (PMID: 17919502, 24706876). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Sep 23, 2024 | This missense variant replaces leucine with serine at codon 641 of the ATP7B protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant does not impact protein expression, copper transport activity, and binding to COMMD1 (PMID: 17919502, 24706876). This variant has been reported in individuals affected with Wilson disease (PMID: 15967699, 16088907, 22677543, 23518715, 30232804, 34400371) as well as in unaffected individuals (PMID: 30097039, 34620762). This variant has been identified in 130/280986 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 13, 2024 | - - |
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 26, 2024 | Published functional studies demonstrated that p.(L641S) behaved similarly to the wild-type protein (PMID: 24706876, 17919502); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 15967699, 23518715, 17919502, 18371106, 34426522, Cumpata2022[Review], 34400371, 36096368, 34620762, 35132767, 30097039, 32248359, 39502306, 24253677, 22677543, 16088907, 24706876) - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jan 05, 2021 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 14, 2021 | Variant summary: ATP7B c.1922T>C (p.Leu641Ser) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0005 in 251632 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in ATP7B causing Wilson Disease (0.0005 vs 0.0054), allowing no conclusion about variant significance. The variant c.1922T>C has been reported in the literature in individuals affected with Wilson Disease (example: Cox_2005, Vrabelova_2005, Bost_2012, Ferenci_2019), however, in most of these cases no full gene sequencing was performed, and/or the other pathogenic variant in trans was not specified and/or phase was not provided. These data therefore do not allow clear conclusions about the variant significance. Publications also reported experimental evidence evaluating an impact on protein function. These results showed no damaging effect of this variant on protein localization, copper transport activity, and copper-responsive trafficking (Braiterman_2014) and no effect on interaction with COMMD1 (de Bie_2007). Seven other ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance (n=5) or likely benign (n=2). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 30, 2022 | The c.1922T>C (p.L641S) alteration is located in exon 6 (coding exon 6) of the ATP7B gene. This alteration results from a T to C substitution at nucleotide position 1922, causing the leucine (L) at amino acid position 641 to be replaced by a serine (S). The altered amino acid is conserved throughout evolution:_x000D_ _x000D_ The p.L641 amino acid is conserved in available vertebrate species. The p.L641S alteration is predicted to be deleterious by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at